BioXcel Therapeutics
Price & Volume
Stats
See more52W Range | $1.72-$49.58 |
Market Cap | $7.8M |
Shares Short | 284,534 |
Financials
See moreRevenue (12 Mos) | $2.2M |
Revenue Growth (YoY) | -37.2% |
Gross Profit (12 Mos) | $251,000 |
Diluted EPS | -$34.59 |
News
See moreYahoo Finance • 18 days ago
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Yahoo Finance • 22 days ago
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Yahoo Finance • 24 days ago
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
Yahoo Finance • 25 days ago
BioXcel Therapeutics Announces $14 Million Registered Direct Offering
About
CEO | Dr. Vimal D. Mehta Ph.D. |
CFO | Mr. Richard I. Steinhart MBA |
Address | 555 Long Wharf Drive, New Haven, CT, United States, 06511 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 74 |
